Clicky

Protalix Biotherapeutics Inc(PLX)

Description: Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.


Keywords: Biotechnology Biopharmaceutical Life Sciences Rare Diseases Cystic Fibrosis Gout Lipid Storage Disorders Gaucher Disease Treatment Of Cystic Fibrosis Fabry Diseases Pro Cell Ex Protalix Biotherapeutics

Home Page: www.protalix.com

2 University Plaza
Hackensack, NJ 07601
United States
Phone: 201 696 9345


Officers

Name Title
Mr. Dror Bashan Pres, CEO & Director
Mr. Eyal Rubin M.B.A. Sr. VP, CFO, Treasurer & Corp. Sec.
Mr. Yaron Naos Sr. VP of Operations
Ms. Yael Fellous VP of HR

Exchange: TA

Country: IL

Currency: Israeli Agora (ILA)

Forward PE: 119.0476
Trailing PE: 0
Price-to-Book MRQ: 215.1263
Price-to-Sales TTM: 4.3764
IPO Date:
Fiscal Year End: December
Full Time Employees: 202
Back to stocks